Last reviewed · How we verify
Beclomethasone dipropionate HFA
Beclomethasone dipropionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator release.
Beclomethasone dipropionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator release. Used for Asthma maintenance and prophylaxis, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Beclomethasone dipropionate HFA |
|---|---|
| Also known as | QVAR® 40 mcg or QVAR® 80 mcg, Qvar |
| Sponsor | National Jewish Health |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
As an inhaled corticosteroid, beclomethasone dipropionate acts locally in the lungs to inhibit inflammatory cell activation and reduce production of inflammatory cytokines and mediators. This decreases airway edema, mucus production, and hyperresponsiveness, leading to improved airflow and reduced asthma symptoms. The HFA (hydrofluoroalkane) formulation provides efficient drug delivery to the lower respiratory tract.
Approved indications
- Asthma maintenance and prophylaxis
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Tremor
- Headache
- Dysphonia
- Throat irritation
Key clinical trials
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
- Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma (PHASE3)
- Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma. (PHASE3)
- Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (PHASE2)
- An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects (PHASE2)
- Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beclomethasone dipropionate HFA CI brief — competitive landscape report
- Beclomethasone dipropionate HFA updates RSS · CI watch RSS
- National Jewish Health portfolio CI